Search research articles
Contact Us
Filters
Showing results (141-150 of 171) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules
George D Demetri, Sant P Chawla, Margaret von Mehren, et al.
The Lancet. Oncology
|
April 13, 2015
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
Jean-Yves Blay, Zsuzsanna Pápai, Anthony W Tolcher, et al.
Cancer
|
April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas
Robin L Jones, Sant P Chawla, Steven Attia, et al.
Anticancer Research
|
October 3, 2018
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
N Penel, G D Demetri, J Y Blay, et al.
Cancer
|
June 8, 2019
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
Shreyaskumar Patel, Margaret von Mehren, Damon R Reed, et al.
The Oncologist
|
January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
Suzanne George, Robin L Jones, Sebastian Bauer, et al.
Future Oncology (London, England)
|
April 15, 2021
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
Mrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, et al.
BMJ Open
|
May 2, 2025
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Timothy Price, Iwona Lugowska, Sant P Chawla, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 171) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules
George D Demetri, Sant P Chawla, Margaret von Mehren, et al.
The Lancet. Oncology
|
April 13, 2015
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
Jean-Yves Blay, Zsuzsanna Pápai, Anthony W Tolcher, et al.
Cancer
|
April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas
Robin L Jones, Sant P Chawla, Steven Attia, et al.
Anticancer Research
|
October 3, 2018
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
N Penel, G D Demetri, J Y Blay, et al.
Cancer
|
June 8, 2019
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
Shreyaskumar Patel, Margaret von Mehren, Damon R Reed, et al.
The Oncologist
|
January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
Suzanne George, Robin L Jones, Sebastian Bauer, et al.
Future Oncology (London, England)
|
April 15, 2021
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
Mrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, et al.
BMJ Open
|
May 2, 2025
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Timothy Price, Iwona Lugowska, Sant P Chawla, et al.
Page
of 18